NASDAQ:NTLA - Intellia Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Intellia Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $15.08 -0.08 (-0.53 %) (As of 01/17/2020 01:25 PM ET) Add Compare Today's Range$14.72Now: $15.08▼$15.3850-Day Range$13.87MA: $15.83▼$17.6752-Week Range$10.26Now: $15.08▼$19.00Volume464,801 shsAverage Volume610,382 shsMarket Capitalization$737.14 millionP/E RatioN/ADividend YieldN/ABeta2.77 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NTLA Previous Symbol CUSIPN/A CIK1652130 Webhttp://www.intelliatx.com/ Phone857-285-6200Debt Debt-to-Equity Ratio0.05 Current Ratio7.89 Quick Ratio7.89Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$30.43 million Price / Sales24.22 Cash FlowN/A Price / Cash FlowN/A Book Value$6.40 per share Price / Book2.36Profitability EPS (Most Recent Fiscal Year)($1.98) Net Income$-85,340,000.00 Net Margins-225.54% Return on Equity-33.00% Return on Assets-25.98%Miscellaneous Employees211 Outstanding Shares48,882,000Market Cap$737.14 million Next Earnings Date2/26/2020 (Estimated) OptionableOptionable Receive NTLA News and Ratings via Email Sign-up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:NTLA Rates by TradingView Intellia Therapeutics (NASDAQ:NTLA) Frequently Asked Questions What is Intellia Therapeutics' stock symbol? Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA." How were Intellia Therapeutics' earnings last quarter? Intellia Therapeutics Inc (NASDAQ:NTLA) released its quarterly earnings results on Thursday, October, 31st. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.12. The business had revenue of $10.60 million for the quarter, compared to analysts' expectations of $9.17 million. Intellia Therapeutics had a negative net margin of 225.54% and a negative return on equity of 33.00%. The firm's revenue for the quarter was up 43.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.53) earnings per share. View Intellia Therapeutics' Earnings History. When is Intellia Therapeutics' next earnings date? Intellia Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Intellia Therapeutics. What price target have analysts set for NTLA? 7 analysts have issued twelve-month price objectives for Intellia Therapeutics' shares. Their forecasts range from $16.00 to $57.50. On average, they anticipate Intellia Therapeutics' share price to reach $26.92 in the next twelve months. This suggests a possible upside of 79.6% from the stock's current price. View Analyst Price Targets for Intellia Therapeutics. What is the consensus analysts' recommendation for Intellia Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intellia Therapeutics. What are Wall Street analysts saying about Intellia Therapeutics stock? Here are some recent quotes from research analysts about Intellia Therapeutics stock: 1. According to Zacks Investment Research, "Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR-Cas9 technology and create a new class of therapeutic products. " (1/15/2020) 2. Chardan Capital analysts commented, "We see the Alnylam experience as particularly relevant given parallels between the 2 companies’ pipelines (transthyretin amyloidosis, primary hyperoxaluria) as well as the use of lipid-nanoparticle (LNP) technology to deliver CRISPR/Cas RNAs (Intellia) or siRNA therapeutics (Alnylam) to the liver. Dr Sepp-Lorenzino also has experience in delivery of nucleotide therapies outside the liver. Given Intellia’s prior work on delivery of LNPs to the central nervous system, to us, this appointment could signal further non-liver pipeline expansion in the longer term. Is the tide of CRISPR management departures turning? In our 22 January 2019 research, we noted the trend of executive turnover/ departures at the helm of CRISPR gene editing companies that occurred over the course of 2018/early-19." (5/28/2019) Has Intellia Therapeutics been receiving favorable news coverage? Press coverage about NTLA stock has been trending very negative on Friday, InfoTrie reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Intellia Therapeutics earned a coverage optimism score of -3.6 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Intellia Therapeutics. Who are some of Intellia Therapeutics' key competitors? Some companies that are related to Intellia Therapeutics include Myriad Genetics (MYGN), Heska (HSKA), Lantheus (LNTH), Quotient (QTNT), Oxford Immunotec Global (OXFD), Meridian Bioscience (VIVO), Nymox Pharmaceutical (NYMX), Vermillion (VRML), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Arca Biopharma (ABIO), GeneNews (GNWSF) and Achieve Life Sciences (ACHV). What other stocks do shareholders of Intellia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), Crispr Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Canopy Growth (CGC), Netflix (NFLX) and QUALCOMM (QCOM). Who are Intellia Therapeutics' key executives? Intellia Therapeutics' management team includes the folowing people: Dr. John M. Leonard, Pres, CEO & Director (Age 62)Mr. Nessan Bermingham Ph.D., Founder & Member of Scientific Advisor Board (Age 46)Mr. José E. Rivera, Exec. VP & Gen. Counsel (Age 53)Ms. Rachel Haurwitz Ph.D., Co-Founder (Age 33)Mr. Andrew May Ph.D., Founder and Member of Scientific Advisor Board When did Intellia Therapeutics IPO? (NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager. How do I buy shares of Intellia Therapeutics? Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Intellia Therapeutics' stock price today? One share of NTLA stock can currently be purchased for approximately $14.99. How big of a company is Intellia Therapeutics? Intellia Therapeutics has a market capitalization of $732.62 million and generates $30.43 million in revenue each year. The company earns $-85,340,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis. Intellia Therapeutics employs 211 workers across the globe.View Additional Information About Intellia Therapeutics. What is Intellia Therapeutics' official website? The official website for Intellia Therapeutics is http://www.intelliatx.com/. How can I contact Intellia Therapeutics? Intellia Therapeutics' mailing address is 40 ERIE STREET SUITE 130, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-285-6200 or via email at [email protected] MarketBeat Community Rating for Intellia Therapeutics (NASDAQ NTLA)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 288 (Vote Outperform)Underperform Votes: 253 (Vote Underperform)Total Votes: 541MarketBeat's community ratings are surveys of what our community members think about Intellia Therapeutics and other stocks. Vote "Outperform" if you believe NTLA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTLA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/17/2020 by MarketBeat.com StaffFeatured Article: Range Trading
